Conference Programme
Maximising Returns from Life Science Innovation
4 December 2024
Maximising Returns from Life Science Innovation
Programme
The 2024 Keynote Programme at Genesis will explore the exciting potential offered by innovation in life sciences offers to address global health, economic and sustainability challenges. Whilst the sessions will also discuss how the barriers to progress can be defeated through creative thinking in R&D, collaboration, investment, and patient access to translate the golden triangle of ‘technology-people-money’ into creation for all stakeholders.
.
Registration
Welcome from One Nucleus
Tony Jones, CEO, One Nucleus
Session Sponsor
Keynote Address – Financial Markets and What to Expect Next
With the US seen as the key market for UK life science companies and international VCs contributing the majority of the essential growth investment for UK biotechs (US > 30% in 2023), what’s happening in the global money markets and what does that mean for Life Sciences?
Will Walker-Arnott, Charles Stanley, David Stubbs, Raymond James
Panel: Mansion or Maisonette?
With the new UK Government continuing to back policies to enable Life Sciences to be a key driver of economic growth, including pension reforms, tech transfer support and R&D tax incentives, what is a realistic aspiration for the UK sector?
Moderator: Timothy H. Ehrlich, Gunderson Dettmer
Panellists: Eric Mayes, Endomag, Sarah Haywood, Advanced Oxford, David Stubbs, Raymond James, Tony Hickson, Cancer Research Horizons, George Freeman MP
How Can Collaborators Extract Maximal Value From Data?
Antima Gupta, Collaborative Drug Discovery
Coffee Break
Session Sponsor
Session MC: Russell Oakley, CK Group
Keynote Address: Winner & Losers 2024
Mike Ward, Clarivate
Panel: What Happens After the Deal is Signed?
Panel Sponsor:
Discussions about the art of dealmaking normally focus on the partner search, the courtship dance, negotiation, due diligence and finally the deal getting signed. Yet in many ways, that is just the start. How should the dealmaking parties interact post-deal to maximise the value creation going forward?
Moderator: Rienk Pypstra, tranScrip
Panellists: Amanda Lehmann, Astex Pharmaceuticals, Anji Miller, LifeArc, Louise Jopling, Babraham Research Campus, Jane Winter, Seuss+, Rachel Bradley, Penningtons Manches Cooper, Jenny Laird, Eli Lilly
Fireside Chat: Being a Patient Champion
Collectively and as individuals, the attraction of working in the Life Sciences industry is grounded in the desire to improve patients’ lives. How do you address the challenges of enabling patients and R&D leaders to understand each other’s priorities?
Elin Haf Davies, Aparito, Elaine Warburton, OBE, Javelo
Lunch
Session Sponsor:
Session MC: Ayokunmi Ajetunmobi, Pioneer Group
Panel: Why My Technology Would Appear Cheap at Twice the Price?
Panel Sponsor:
Valuation is one of the most debated elements of any deal or transaction. This panel will discuss
(i) how the innovator should create and defend their proposed valuation
(ii) how the investor or buyer assesses the innovator’s homework
(iii) how do you know when to sign or walk away?
Moderator – Michael O’Kane, CoolReach Logistics
Panellists: Michael Murray, Murray International Partners, Claire Thompson, Agility Life Science, Barbara Domayne-Hayman, Francis Crick Institute, Claire Brown, Oxford Science Enterprises, Ayokunmi Ajetunmobi, Pioneer Group
Keynote Address: Introducing Disruptive Technologies: Lessons from a Passionate Entrepreneur
Elin Haf Davies, Aparito
Panel: Watch This Space!
With the pace of change increasing, sector commentators will discuss what they are most looking forward to writing about in the coming year.
Moderator: Femida Gwadry-Sridhar, Pulse Infoframe
Panellists: Megan Thomas, Drug Discovery World, Victoria English, MedNous, Lisa Melton, Nature Biotechnology, Lisa Urquhart, Healthcare Journalist, Mike Ward, Clarivate
Coffee Break
Fireside Chat: Will the New Political Landscape Be Good for Life Sciences?
David Rosenberg, Indiana Secretary of Commerce, Mike Ward, Clarivate
Panel: Biology and Technology – Where Do You Fit and Who Does it Matter To?
Panel Sponsor:
With the explosion of new terminology to describe the science of living things, such as Biotech, TechBio, Deep Biotech, Agri-Tech and HealthTech this panel will discuss where companies find their sense of identity when developing their value proposition.
Moderator: Aline Charpentier, Bruntwood SciTech
Panellists: Belinda Clarke, Agri-TechE, Catherine Stace, Kuano, Alicia Showering, BugBiome, Abigail Martin, ImmuONE
Fireside Chat – How does the UK plc CV Look to a Leading Bioentrepreneur?
Renos Savva, Discovery Park, Nara Daubeney, Phaim
Panel: Inside the Mind of a Life Science Investor
Panel Sponsor:
How much of investment decision-making is an art and how much is science? This panel of investment leaders will discuss their approach to selecting the right deals.
Moderator: Phil Masterson, Cancer Research Horizons
Panellists: Anne Horgan, Cambridge Innovation Capital, Kerstin Papenfuss, Deep Science Ventures, Markus Dietrich, Hadean Ventures, Jonathan Tobin, Brandon Capital/Cancer Research Horizons, Laura Lane, Eli Lilly
Closing Remarks
Tony Jones, One Nucleus
Genesis – RESI London Drinks Reception
Close
Programme is subject to change